Matrix metalloprotease regulation of neuropathic pain

Trends in Pharmacological Sciences

Volumn 30, Issue 7, 2009, Pages 336-340

  Ji, Ru Rong ^a   Xu, Zhen Zhong ^a   Wang, Xiaoying ^b   Lo, Eng H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CHRONIC PAIN; NERVE CELL; NERVE INJURY; NEUROGENIC INFLAMMATION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; SPINAL CORD; SPINAL CORD INJURY; SPINAL GANGLION; STELLATE CELL;

ANIMALS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEURALGIA; PAIN; PROTEASE INHIBITORS;

EID: 67649394340     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.04.002     Document Type: Article

References (49)

1. Woolf C.J., and Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353 (1999) 1959-1964
2. Dworkin R.H., et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol. 60 (2003) 1524-1534
3. Ji R.R., and Strichartz G. Cell signaling and the genesis of neuropathic pain. Sci. STKE 2004 (2004) reE14
4. Kehlet H., et al. Persistent postsurgical pain: risk factors and prevention. Lancet 367 (2006) 1618-1625
5. Polomano R.C., and Bennett G.J. Chemotherapy-evoked painful peripheral neuropathy. Pain Med. 2 (2001) 8-14
6. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
7. Seltzer Z., et al. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43 (1990) 205-218
8. Kim S.H., and Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50 (1992) 355-363
9. Decosterd I., and Woolf C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87 (2000) 149-158
10. Julius D., and Basbaum A.I. Molecular mechanisms of nociception. Nature 413 (2001) 203-210
11. Woolf C.J., and Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 288 (2000) 1765-1769
12. Ji R.R., et al. Central sensitization and LTP: do pain and memory share similar mechanisms?. Trends Neurosci. 26 (2003) 696-705
13. Sommer C., and Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci. Lett. 361 (2004) 184-187
14. Schafers M., et al. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-α after spinal nerve ligation. J. Neurosci. 23 (2003) 3028-3038
15. Kawasaki Y., et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat. Med. 14 (2008) 331-336
16. Jin X., and Gereau IV R.W. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-α. J. Neurosci. 26 (2006) 246-255
17. Binshtok A.M., et al. Nociceptors are interleukin-1β sensors. J. Neurosci. 28 (2008) 14062-14073
18. Coull J.A., et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438 (2005) 1017-1021
19. Kawasaki Y., et al. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1β, interleukin-6, and tumor necrosis factor-α in regulating synaptic and neuronal activity in the superficial spinal cord. J. Neurosci. 28 (2008) 5189-5194
20. Watkins L.R., et al. Glial activation: a driving force for pathological pain. Trends Neurosci. 24 (2001) 450-455
21. Scholz J., and Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10 (2007) 1361-1368
22. Milligan E.D., and Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 10 (2009) 23-36
23. Tsuda M., et al. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci. 28 (2005) 101-107
24. Ji R.R., et al. Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway. Neuron Glia Biol. 2 (2006) 259-269
25. Raghavendra V., et al. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306 (2003) 624-630
26. Zhuang Z.Y., et al. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J. Neurosci. 26 (2006) 3551-3560
27. DeLeo J.A., and Yezierski R.P. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90 (2001) 1-6
28. Milligan E.D., et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci. 23 (2003) 1026-1040
29. Sweitzer S., et al. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 103 (2001) 529-539
30. Guo W., et al. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J. Neurosci. 27 (2007) 6006-6018
31. Jin S.X., et al. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J. Neurosci. 23 (2003) 4017-4022
32. Zhuang Z.Y., et al. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 114 (2005) 149-159
33. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 39 (2002) 279-291
34. Parks W.C., et al. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4 (2004) 617-629
35. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 6 (2005) 931-944
36. Manicone A.M., and McGuire J.K. Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol. 19 (2008) 34-41
37. Hu J., et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6 (2007) 480-498
38. Murphy G., and Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 248 (1995) 496-510
39. Wang X., et al. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J. Neurosci. 20 (2000) 7037-7042
40. Zhao B.Q., et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 12 (2006) 441-445
41. Yong V.W., et al. The promise of minocycline in neurology. Lancet Neurol. 3 (2004) 744-751
42. Murata Y., et al. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 39 (2008) 3372-3377
43. Clark A.K., et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 10655-10660
44. Komori K., et al. Absence of mechanical allodynia and Aβ-fiber sprouting after sciatic nerve injury in mice lacking membrane-type 5 matrix metalloproteinase. FEBS Lett. 557 (2004) 125-128
45. Chattopadhyay S., et al. Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve. Brain Behav. Immun. 21 (2007) 561-568
46. Schonbeck U., et al. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 161 (1998) 3340-3346
47. Wilczynski G.M., et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J. Cell Biol. 180 (2008) 1021-1035
48. Gordon P.H., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6 (2007) 1045-1053
49. Rodriguez Parkitna J., et al. Comparison of gene expression profiles in neuropathic and inflammatory pain. J. Physiol. Pharmacol. 57 (2006) 401-414